Modexa (140 Sprays)
Indonesia • Dexa Medica
Indication
Seasonal or perennial Rhinitis
Modexa nasal spray is indicated for use in adults, adolescents and children between the age of 2 and 11 years to treat the symptoms of seasonal or perennial rhinitis, especially in moderate to severe persistent allergy.
Nasal polyps
Modexa nasal spray is also indicated for the treatment of nasal polyps in adults 18 years of age and older.
Acute Rhinosinusitis
Modexa nasal spray is indicated for the treatment of symptoms associated with mild to moderate uncomplicated acute rhinosinusitis in adults and children 12 years of age and older where signs or symptoms of bacterial infection are not present.
Composition
Mometasone 0.05 %
Package
Dosage Forms
Nasal SprayATC Classification
Warning
Dosage
0 to 2 Years Old
Not recommended.
2 to 11 Years Old
Seasonal allergic or perennial rhinitis:
The usual recommended dose is 1 spray (50 mcg/spray) in each nostril once daily (total dose 100 mcg). Administration to young children should be aided by an adult.
Nasal polyposis:
Safety and efficacy of Modexa nasal spray for the treatment in children have not been studied.
12 to 18 Years Old
Seasonal allergic or perennial rhinitis:
The usual recommended dose for prophylaxis and treatment is 2 sprays (50 mcg/spray) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to 1 spray in each nostril (total dose 100 mcg) may be effective for maintenance.
If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of 4 sprays in each nostril once daily (total dose 400 mcg). Dose reduction is recommended following control of symptoms.
Nasal polyposis:
Safety and efficacy of Modexa nasal spray for the treatment in adolescents under 18 years of age have not been studied.
18 Years Old and Above
Seasonal allergic or perennial rhinitis:
The usual recommended dose for prophylaxis and treatment is 2 sprays (50 mcg/spray) in each nostril once daily (total dose 200 mcg). Once symptoms are controlled, dose reduction to 1 spray in each nostril (total dose 100 mcg) may be effective for maintenance.
If symptoms are inadequately controlled, the dose may be increased to a maximum daily dose of 4 sprays in each nostril once daily (total dose 400 mcg). Dose reduction is recommended following control of symptoms.
Nasal polyposis:
The usual recommended starting dose for polyposis is 2 sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg). Once symptoms are adequately controlled, dose reduction to two sprays in each nostril once daily (total daily dose 200 mcg) is recommended. Efficacy and safety of Modexa nasal spray for the treatment of nasal polyps were four months in duration
Treatment of Mild to Moderate Uncomplicated Acute Rhinosinusitis:
The usual recommended dose for acute rhinosinusitis is two sprays (50 mcg/spray) in each nostril twice daily (total daily dose of 400 mcg). If symptoms worsen during treatment, the patient should be advised to consult their physician.
The therapeutic effects of corticosteroids, unlike those of decongestants, are not immediate. Since the effect of Modexa nasal spray depends on its regular use, patients should be instructed to take the nasal inhalation at regular intervals and not, as with other nasal sprays, as they feel necessary.
In the presence of excessive nasal mucous secretion or edema of the nasal mucosa, the drug may fail to reach the site of action. In such cases, it is advisable to use a nasal vasoconstrictor for 2 to 3 days prior to starting treatment with Modexa nasal spray. Patients should be instructed on the correct method of use, which is to blow the nose, then insert the nozzle carefully into the nostril, compress the opposite nostril and actuate the spray while inspiring through the nose, with the mouth closed.